Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.05, Bloomberg Earnings reports. The company had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $1.28 million. Chimerix had a negative net margin of 1,514.27% and a negative return on equity of 24.68%.
Shares of Chimerix (NASDAQ:CMRX) traded down 1.14% on Friday, hitting $4.35. The company had a trading volume of 140,130 shares. The company has a 50 day moving average price of $4.98 and a 200 day moving average price of $5.41. The firm’s market capitalization is $204.65 million. Chimerix has a 1-year low of $3.66 and a 1-year high of $6.64.
CMRX has been the subject of several recent analyst reports. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Wednesday, August 9th. FBR & Co reaffirmed a “hold” rating and set a $7.00 price target on shares of Chimerix in a report on Monday, May 1st. Cowen and Company reaffirmed a “hold” rating and set a $6.00 price target on shares of Chimerix in a report on Friday, April 28th. Finally, ValuEngine downgraded Chimerix from a “hold” rating to a “sell” rating in a report on Friday, August 11th.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
What are top analysts saying about Chimerix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chimerix Inc. and related companies.